



Enzymatica
THE SCIENCE THAT PROTECTS

Year-end report

January–December 2025

Enzymatica AB develops health products based on Penzyme® technology, which contains marine enzymes. The main product is ColdZyme® – a mouth spray for colds and cold-like symptoms in the upper respiratory tract. The Group's strategy is to grow by strengthening its position in existing markets and expanding internationally through established partners. Enzymatica is headquartered in Lund and is listed on Nasdaq First North Growth Market. Certified Adviser is DNB Carnegie Investment Bank AB (publ). For more information please visit [.](#)

Enzymatica AB (publ)

Year-end report January–December 2025

Q4

- Net sales reached SEK 18.3 (17.2) million.
- The operating result totaled SEK -10.2 (-13.7) million.
- Earnings per share, basic and diluted, were SEK -0.05 (-0.05).
- Cash flow from operating activities totaled SEK 0.5 (-20.6) million.

January–December

- Net sales reached SEK 53.9 (45.6) million.
- The operating result totaled SEK -51.4 (-52.1) million.
- Earnings per share, basic and diluted, were SEK -0.21 (-0.28).
- Cash flow from operating activities for the period totaled SEK -41.0 (-60.5) million.
- Net cash totaled SEK 32.1 (73.0) million at year-end.

Key figures

(SEK million)	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Net sales	18.3	17.2	53.9	45.6
Gross margin, %	60	67	61	67
Operating profit/loss	-10.2	-13.7	-51.4	-52.1
Cash flow from operating activities	0.5	-20.6	-41.0	-60.5
Net debt/Net cash			32.1	73.0
Average number of employees	21	21	21	18

“My ambition is to drive our partner processes through to agreements that create long-term value for Enzymatica’s shareholders.”

Sana Alajmovic, CEO



Enzymatica AB (publ)

Year-end report January–December 2025

Significant events during the quarter

- On October 13, Enzymatica announced the appointment of Holger Lembrér as the new CFO, effective no later than April 2026.

Significant events after the quarter

- No significant events were reported after the end of the quarter.

Other events during and after the quarter

- In October, ColdZyme Eucalyptus was launched as the latest flavor in the ColdZyme® range. The product offers the same clinically proven effect as the other flavors and was introduced to the Swedish market as a new option alongside menthol and strawberry.
- Enzymatica strengthened its position in elite sport through three strategic partnerships – with the Swedish Biathlon Federation as Official Supplier ahead of Milan 2026 and with British GB Snowsport and the UK Sports Institute (UKSI), collectively strengthening ColdZyme's presence in high-performance sporting environments in Sweden and the United Kingdom.
- On 1 February, Sana Alajmovic was appointed Chief Executive Officer of Enzymatica AB.
- Following the appointment of the new CEO, the Board of Directors has initiated a review of Enzymatica's financial targets. Updated targets are intended to be presented in the latter part of 2026.



CEO Sana Alajmovic:

The next phase of Enzymatica's international expansion



In connection with my appointment as CEO of Enzymatica, I have prioritized establishing a more structured approach to partnerships. I join the company with strong confidence in the potential of both the product and the organization, and I see good opportunities to build further on the platform already in place.

When I assumed the role of CEO of Enzymatica, I encountered a company that had already established a clear position in the market. ColdZyme is a product that delivers results, is appreciated by consumers, and has built strong loyalty over time. The work carried out across research, marketing, and sales provides a favorable starting point for the next phase.

During my first weeks, I have placed strong emphasis on gaining a thorough understanding of the business and forming a clear view of both its current position and future potential. I am meeting an organization with deep expertise, high engagement, and a shared ambition to take ColdZyme into its next phase of growth.

I have already had the opportunity to meet with international players and initiate discussions around potential partnerships, and the interest I am seeing confirms the opportunity ahead. With a clear strategy in place, the next step is to accelerate execution and expand the company's international presence.

The quarter and the year in brief

Below is a summary of performance for the quarter and the full year. During the fourth quarter, sales continued to develop positively, with net sales of SEK 18.3 million (SEK 17.2 million). For the full year, net sales amounted to SEK 53.9 million, representing growth of 18.3% compared with 2024.

During 2025, ColdZyme's pharmacy sales in Sweden increased by 12.1% in value compared with full-year 2024, despite the overall cold market in pharmacies growing by only 3.3%. This means that ColdZyme grew nearly four times faster than the market overall and increased its market share to 5.8%, up from 5.3% in 2024 (source: IQVIA).

Strengthened positioning in the Swedish market

The new campaign, "Win Faster Against Every Cold," launched in the autumn, has contributed to broadening ColdZyme's positioning by shifting the focus from preventive use to treatment at early symptoms. This significantly expands our potential addressable market. The campaign message provides a strong foundation going into 2026, as ColdZyme is the only cold mouth spray that has demonstrated clinical evidence of shortening the duration of the common cold.

Partnerships – the Fastest path to Increased sales

The evaluation and negotiation of partnerships in Europe are already underway. Together with the company's team, I have held initial meetings with several international players and am experiencing strong interest in ColdZyme and its unique positioning. ColdZyme's scientific strength, including the most recent publication in the Journal of Physiology from February 2025, provides us with a competitive starting point in these discussions. Our ambition is, of course, to drive these partner processes through to agreements that create long-term value for Enzymatica's shareholders.

In parallel, we continue to develop our brand, intensify our marketing efforts, and build an efficient and scalable organization that is well positioned for international expansion. More concrete updates will be communicated in due course.

Review of the company's financial targets

In connection with my appointment as CEO, the Board of Directors has initiated a review of the company's financial targets. The intention is to present updated targets during the latter part of 2026. The purpose is to ensure that the target framework fully supports our long-term strategy and creates long-term shareholder value.

Outlook

As we approach 2026, Enzymatica stands on a solid scientific foundation, with a product that makes a real difference and an organization ready to take the next step internationally. Much important work has already been completed—now the focus is on accelerating execution. I enter this phase with strong momentum and clear ambition, and I see significant opportunities to scale Enzymatica's innovations internationally together with the team.

Sana Alajmovic
CEO, Enzymatica AB



Enzymatica's business concept is to develop self-care products, based on the Group's barrier technology platform. The parent company was founded in 2007, has its head office in Lund, Sweden, and has been listed on the Nasdaq First North Growth Market since 2015.

Enzymatica has developed ColdZyme, a unique mouth spray for colds. Sales are handled in Sweden and the United Kingdom through contract organizations, while distribution in other markets takes place through partnership agreements with leading players in consumer healthcare – an area that remains a high priority for further development.

Enzymatica's development work is focused on products related to upper respiratory tract infections. Research and development is led from Lund, in close collaboration with the production facility in Iceland.

Enzymatica's research is carried out in collaboration with renowned universities and research groups. Studies are carried out both independently and on behalf of the Group. The latest independent studies, conducted by researchers at the University of Kent and the University of Vienna, were published in *The Journal of Physiology* in February 2025.

Seasonal variations

Cold products usually have a seasonal peak in the winter in the northern hemisphere, while sales level out in the summer months.

Financial targets

In connection with the appointment of the new CEO, the Board of Directors has initiated a review of Enzymatica's financial targets. In light of this, the previously communicated EBIT target of at least approximately SEK 170 million by the end of 2027 is under review. Updated targets are intended to be presented during the latter part of 2026.

Markets

The randomized, double-blind, placebo-controlled study is a key component of Enzymatica's strategy for international expansion and the relaunch of ColdZyme in Europe. The MDR certification that ColdZyme received in 2024 creates important conditions for international establishment.

In the United Kingdom, the independent study makes it possible to market ColdZyme directly to consumers, as such a study is required to support the product's claims.

Building on the clinical research findings – and the product claims and classifications that are now being refined based on these – the company continues its efforts to identify the most effective commercial pathways forward.



The new flavor **ColdZyme Eucalyptus** was launched on the Swedish market in October and is the latest addition to the ColdZyme range.



Sales and market

Net sales in the fourth quarter of 2025 came in at SEK 18.3 (17.2) million – a 6.8% increase compared with the same period in 2024. Adjusted for currency fluctuations, sales increased by 9.1%.

The increase is driven mainly by growth in the United Kingdom and Iceland, but also by an order from an existing partner in South Africa.

The cold market in Swedish pharmacies declined by 4.0% in value during the quarter compared with the same quarter in 2024. Against this backdrop, ColdZyme's pharmacy sales increased by 6.6% in value over the same period. As a result, ColdZyme significantly outperformed the market overall and increased its share of the total cold market, measured by value, to 6.38%, compared with 5.74% in the corresponding period of the previous year (source: IQVIA).

Performance

The gross margin during the quarter was 60% (67).

Enzymatica has experienced variations in gross margins between individual quarters. The gross margin for the quarter was affected by increased costs to the Group's manufacturing partner for our rights to their packaging line.



Total operating expenses for the quarter amounted to SEK 21.8 (25.7) million. The decrease is primarily due to lower administrative expenses. No expenses for development projects were capitalized during the quarter (0).

The consolidated operating loss was SEK -10.2 (-13.7) million. Net financial income and expenses for the period amounted to SEK -0.7 (0.4) million. Tax expense for the period was SEK -0.1 (0.0) million. Impairment charges totaled SEK 1.3 (1.4) million.

Research, development and other investments

Total consolidated research and development expenses were in line with the plan and amounted to SEK 3.9 (4.3) million for the fourth quarter. The Group's investments in

property, plant and equipment and intangible assets for the quarter totaled SEK 0.0 (0.2) million, of which SEK 0 (0) million are intangible assets.



Sales

Consolidated net sales for 2025 came in at SEK 53.9 (45.6) million, an increase of 18.3% compared with the same period in 2024. Adjusted for currency fluctuations, sales increased by 19.3%.

For the full year 2025, ColdZyme's pharmacy sales increased by 12.1 percent in value compared with the full year 2024, versus market growth of 3.3 percent. This means that ColdZyme grew almost four times faster than the market as a whole and reached a market share of 5.8 percent, compared with 5.3 percent in 2024 (Source: IQVIA).

Performance

Gross margin in 2025 was 61% (67). The gross margin for the period was affected by increased costs to the Group's manufacturing partner for our rights to their packaging line.

Total operating expenses for the period January–December were SEK 85.3 (83.5) million. The increase was mainly driven by higher administrative and selling expenses. No expenses for development projects were capitalized during the period SEK 0 (0) thousand.

The consolidated operating loss was SEK -51.4 (-52.1) million. The result for the period was SEK -51.9 million (-53.2). Net cash totaled SEK -0.5 (-1.3) million. Tax expense for the period was SEK 0.0 (0.2) million. Impairment charges totaled SEK 5.4 (5.8) million.

Research, development and other investments

Total consolidated research and development expenses were in line with the plan and amounted to SEK 15.7 (15.5) million.

The Group's investments in property, plant and equipment and intangible assets for 2025 totaled SEK 0.2 (0.4) million, of which SEK 0 (0) million relates to intangible assets.

Funding and cash flow

The Group's available funds at the end of the period totaled SEK 34.6 (76.8) million, of which SEK 33.1 (75.2) million were in cash and cash equivalents and SEK 1.5 (1.6) million in unutilized credit facilities.

Net cash at the end of the period totaled SEK 32.1 (73.0) million. Cash flow from operating activities for 2025 totaled SEK -41.0 (-60.5) million. Cash flow from operating activities for Q4 came in at SEK 0.5 (-20.6) million. Total cash flow for the period amounted to SEK -42.0 (66.8) million.

Parent company

The parent company is responsible for group management and all operational activities, with the exception of enzyme production and the part of research and development that take place within the subsidiary Enzymatica ehf.

The parent company's sales for 2025 reached SEK 51.3 (43.1) million. Loss before tax came in at SEK -52.5 (-50.8) million. The parent company's investments in property, plant & equipment and intangible assets in 2025 totaled SEK 0 (0) million and cash flow was SEK -43.5 (66.6) million. Please see the consolidated figures for more information.

Staff

The number of people employed by the group, converted to full-time positions, was 20 (21) at the end of the period. The employees included 6 (9) men and 14 (12) women.



Other information

Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the following subsidiaries: Enzymatica ehf (corporate identity no. 6406830589), with its head office in Reykjavik, Iceland, and Enzymatica Care AB (corporate identity no. 556701-7495), with its head office in Lund, Sweden.

Accounting policies

The interim report has been prepared in accordance with IAS 34, Interim Financial Reporting. The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, the Swedish Annual Accounts Act, and RFR 1, Supplementary Accounting Rules for Groups. The Parent Company's financial statements are prepared in accordance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities. Disclosures in accordance with IAS 34.16A are provided not only in the financial statements and the related notes, but also in other sections of the interim report.

The accounting policies and valuation principles applied in the Annual Report for 2024 have also been applied in this interim report. Amendments to IFRS standards that became effective during 2025 have not had any material impact on the Group's results or financial position. Apart from IFRS 18, which enters into force in 2027, no material effects on the Group's financial statements are expected from new or amended standards that have not yet become effective. IFRS 18 will impact presentation and disclosures.

Segment reporting

Enzymatica's operations currently include only one operating segment: Medical devices. Please see the consolidated income statement and balance sheet for reporting on this operating segment.

Audit

This report was not reviewed by the Group's auditors.

Incentive program

The Annual General Meeting 2024 resolved to establish the warrant-based incentive program "Warrant Program 2024/2027". The program entails that a maximum of 2,700,000 warrants may be transferred to employees and consultants. The subscription price per share corresponds to 400 percent of the volume-weighted average price (VWAP) according to Nasdaq First North Growth Market's official price list for the parent company's share during a period of ten trading days.

In June 2024, 1,640,000 warrants were allotted and subscribed for at a price of SEK 0.07. In January 2025, 490,000 warrants were allotted and subscribed for at a price of SEK 0.0001 (SEK 0.01 öre). Each warrant entitles the holder to acquire one new share in the parent company at an exercise price of SEK 11.97. Subscription for shares by virtue of the warrants may take place during the period from 1 June 2027 up to and including 30 June 2027. The maximum dilution effect of the allotted warrants amounts to approximately 0.87 percent.

An Extraordinary General Meeting on 22 August 2025 resolved to establish the warrant-based incentive program "Warrant Program 2025/2028". The program entails that a maximum of 2,000,000 warrants may be transferred to employees and consultants. Subscription for shares by virtue of the warrants may take place during the period from 1 October 2028 up to and including 31 December 2028. The subscription price per share corresponds to 200 percent of the volume-weighted average price according to Nasdaq First North Growth Market's official price list for the parent company's share during a period of five trading days. Each warrant entitles the holder to acquire one new share in the parent company at an exercise price of SEK 4.82. In September 2025, 1,000,000 warrants were allotted and subscribed for at a price of SEK 0.39. Full exercise of the warrants within the framework of Warrant Program 2025/2028 entails a maximum dilution effect of approximately 0.82 percent.

Information about risks and uncertainties

Enzymatica's operations are exposed to a number of risks, including operational, regulatory and financial risks.

The operational risks primarily relate to uncertainties associated with distribution, sales, marketing and supplier agreements.

Enzymatica's future expansion is dependent on successful collaborations with various partners. The company's business model is based on its partners being responsible for sales and marketing in their respective local markets, as governed by agreements with each partner. If a partner fails to fulfil its obligations with respect to sales and marketing activities, this could adversely affect Enzymatica's sales and revenues.

Enzymatica's production of the stabilized form of cod trypsin (Penzyme) is currently carried out exclusively at the company's own production facility in Reykjavík, Iceland. A prolonged production interruption could impact the company's ability to meet demand and fulfil its commitments to partners.

Financial risks primarily consist of foreign exchange, credit, financing and liquidity risks. Regulatory risks mainly relate to changes in legislation or other regulatory frameworks. For a more detailed description of the risks and uncertainties facing Enzymatica, please refer to the 2024 Annual Report, available on the Group's website.

Nomination Committee

In accordance with the principles for the Nomination Committee adopted at the Annual General Meeting 2019, the Nomination Committee for the next Annual General Meeting shall consist of representatives of the four largest shareholders registered in the register of shareholders held by Euroclear Sweden AB as of September 30 each year, together with the Chairman of the Board, who shall also convene the Nomination Committee for its first meeting.

The four largest shareholders as of September 30, 2025, were Mats Andersson through Abanico Invest AB and privately, Håkan Roos through Roosgruppen, Björn Algvist through Fibonacci Growth Capital AB and Nucleus Capital AB, and Bengt Baron through 5653 Sweden AB and privately. Together, they comprise Enzymatica's Nomination Committee for the 2026 Annual General Meeting. Mats Andersson has been appointed Chairman of the Nomination Committee.

Annual General Meeting

Enzymatica's 2026 Annual General Meeting will be held in Lund at 2:30 p.m. on May 7, at the Elite Hotel Ideon in Lund, Sweden. Shareholders who wish to have a matter addressed at the Annual General Meeting may send their request in writing by e-mail to sriwarint.olsson@enzymatica.com or by regular mail to the Board of Directors, Enzymatica AB, Ideon Science Park, SE-223 70 Lund, Sweden. The request must be in writing and received no later than seven weeks before the general meeting in order to be included on the agenda of the Annual General Meeting.



Other information

Upcoming financial information

2025 Annual Report	April 14, 2026
Interim report, Jan–March 2026	April 28, 2026
2025 AGM of Shareholders	May 7, 2026
Interim report, Jan–Jun 2026	July 16, 2026
Interim report, Jan–Sep 2026	October 29, 2026

For questions about this report, please contact:

Sana Alajmovic, CEO, Enzymatica AB

+46 723 89 33 96 | sana.alajmovic@enzymatica.com

Therese Filmersson, CFO, and Deputy CEO, Enzymatica AB

+46 (0) 708 40 72 24 | therese.filmersson@enzymatica.com

The interim reports and annual report are available at
www.enzymatica.com.

Year-end report signatures

Lund, February 18, 2026

Publication

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on February 18, 2026.

Street address

Enzymatica AB (publ), corp. ID no. 556719-9244.

Mailing address: Ideon Science Park, 223 70 Lund, Sweden

Street address: Schelevägen 19, Ideon, Lund, Sweden

Tel: +46 (0) 46 286 31 00 | info@enzymatica.com | www.enzymatica.com

Sana Alajmovic

CEO

Enzymatica is listed on the Nasdaq First North Growth Market. The parent company is traded under the ticker symbol ENZY and ISIN code SE0003943620. Certified Adviser is DNB Carnegie Investment Bank AB (publ), certifiedadviser@carnegie.se



Condensed consolidated statement of comprehensive income

All amounts in SEK thousand	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Operating income				
Net sales	18 334	17 161	53 903	45 575
Cost of goods sold	-7 305	-5 636	-20 778	-14 856
Gross profit	11 029	11 525	33 126	30 719
Sales & Marketing expenses	-7 337	-9 987	-27 438	-26 733
Administrative expenses	-10 537	-11 400	-42 236	-41 282
Research and development costs	-3 944	-4 311	-15 659	-15 464
Other operating income	1 098	721	1 296	1 958
Other operating costs	-532	-255	-457	-1 252
Operating profit/loss	-10 223	-13 707	-51 367	-52 055
Profit/loss from financial items				
Interest income and similar profit/loss items	83	519	759	623
Interest expenses and similar profit/loss items	-773	-132	-1 231	-1 906
Profit/loss after financial items	-10 913	-13 320	-51 839	-53 338
Tax expenses	-114	41	-51	159
Profit/loss for the period	-11 027	-13 279	-51 890	-53 179
Other comprehensive income:				
Items that have been redirected or may be included in the profit/loss:				
Translation difference of subsidiaries	-481	506	-695	1 102
Total other comprehensive income, net of tax	-481	506	-695	1 102
Total comprehensive income for the period	-11 507	-12 774	-52 586	-52 077
Share attributable to parent company shareholders	-11 507	-12 774	-52 586	-52 077



Earnings per share

	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Earnings per share, SEK (basic and diluted)	-0,05	-0,05	-0,21	-0,28
Equity per share, SEK	0,51	0,73	0,51	0,73
Equity-asset ratio, %	87%	90%	87%	90%
Number of outstanding shares	242 735 108	242 735 108	242 735 108	242 735 108
Average number of outstanding shares (basic and diluted)	242 735 108	242 735 108	242 735 108	192 731 809

Key financial indicators

Earnings per share

Profit/loss for the period in relation to average weighted number of shares.

Equity per share

Equity in relation to number of shares at the end of the period.

Equity ratio

Equity in relation to total assets.

Net cash/Net debt

Cash and cash equivalents less interest-bearing current and non-current liabilities. A negative amount means net debt.



Quarterly review by auditors

All amounts in SEK thousand	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024
Net sales	18 334	15 007	8 282	12 280	17 161
Gross profit/loss	11 029	9 242	4 380	8 473	11 525
Gross margin in %	60%	62%	53%	69%	67%
Operating costs	-21 818	-17 543	-19 235	-26 737	-25 698
Operating profit/loss	-10 223	-8 231	-14 921	-17 992	-13 707
Profit/loss for the period	-11 027	-8 403	-14 456	-18 005	-13 279
Cash flow	125	-12 215	-21 360	-8 541	-21 731



Condensed consolidated statement of financial position

All amounts in SEK thousand	2025-12-31	2024-12-31	2025-09-30
Assets			
Intangible assets	64 181	66 192	64 684
Tangible assets	10 365	14 399	11 698
Financial assets	2 407	2 637	2 655
Inventories	18 915	16 708	17 971
Trade receivables	9 997	12 090	13 502
Other receivables	2 979	7 985	5 649
Cash and cash equivalents	33 134	75 212	33 080
Total assets	141 978	195 224	149 237
Equity and liabilities			
Equity	124 173	176 369	135 680
Long-term interest-bearing liabilities	8	1 022	190
Current interest-bearing liabilities	1 015	1 179	1 115
Trade payables	8 750	9 812	2 768
Other liabilities	8 033	6 842	9 483
Total equity and liabilities	141 978	195 224	149 237

Condensed consolidated statement of changes in equity

All amounts in SEK thousand	2025-12-31	2024-12-31	2025-09-30
Opening balance	176 369	76 609	176 369
New share issue	-	159 147	-
Issue expenses related to New share issue	-	-7 424	-
Effect of option program	390	115	390
Total comprehensive income for the period	-52 586	-52 077	-41 079
Closing balance	124 173	176 369	135 680



Condensed consolidated statement of cash flows

All amounts in SEK thousand	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Operating profit/loss	-10 223	-13 707	-51 367	-52 055
Adjustments for non-cash items	1 793	434	6 231	5 365
Financial items	-690	387	-472	-1 283
Cash flow from operating activities before changes in working capital	-9 120	-12 886	-45 608	-47 973
Changes in working capital	9 587	-7 665	4 636	-12 534
Cash flow from operating activities	467	-20 551	-40 972	-60 507
Acquisition/disposal of property, plant & equipment	-59	-231	-231	-393
Cash flow from investing activities	-59	-231	-231	-393
Rights Issue	0	0	0	159 147
Issued warrants	0	0	390	115
Transaction costs attributable to new share issue	0	-349	0	-7 424
Change in bank/overdraft facilities/leasing	-283	-600	-1 179	-24 184
Cash flow from financing activities	-283	-949	-789	127 653
Total cash flow for the period	125	-21 731	-41 991	66 753
Cash and cash equivalents at start of period	33 080	96 903	75 212	8 366
Translation difference cash and cash equivalents	-71	40	-87	93
Cash and cash equivalents at end of period	33 134	75 212	33 134	75 212

Note 1: Primarily related to depreciation.



Parent company income statement

All amounts in SEK thousand	Oct-Dec 2025	Oct-Dec 2024	Jan-Dec 2025	Jan-Dec 2024
Operating income				
Net sales	17 632	16 408	51 265	43 129
Cost of goods sold	-11 289	-9 768	-35 682	-27 114
Gross profit	6 343	6 640	15 583	16 015
Sales & Marketing expenses	-6 926	-9 466	-25 820	-25 295
Administrative expenses	-6 194	-7 075	-26 349	-27 616
Research and development costs	-4 320	-4 915	-16 369	-16 625
Other operating income	353	622	79	941
Other operating costs	-84	128	-123	-853
Operating profit/loss	-10 827	-14 066	-52 999	-53 433
Profit/loss from financial items				
Interest income and similar profit/loss items	288	830	1 642	1 483
Interest expenses and similar profit/loss items	-724	-108	-1 120	-1 729
Results from subsidiaries	0	0	0	13 882
Write-down subsidiaries	0	0	0	-11 000
Profit/loss after financial items	-11 263	-13 344	-52 477	-50 797
Tax expenses	0	0	0	0
Profit/loss for the period	-11 263	-13 344	-52 477	-50 797



Parent company balance sheet

All amounts in SEK thousand	2025-12-31	2024-12-31	2025-09-30
Assets			
Intangible assets	1 874	3 886	2 377
Tangible assets	38	31	43
Financial assets	7 452	7 452	7 452
Inventories	17 638	13 823	15 477
Trade receivables	9 793	11 365	13 114
Receivables from group companies	5 162	9 744	7 640
Other receivables	2 005	6 430	3 566
Cash and bank balances	30 490	73 987	32 338
Total assets	74 452	126 717	82 007
Equity and liabilities			
Equity	60 633	112 721	71 896
Long-term interest-bearing liabilities	0	-	0
Current interest-bearing liabilities	0	-	0
Liabilities to group companies	0	-	0
Trade payables	8 164	8 783	2 167
Other liabilities	5 654	5 213	7 943
Total equity and liabilities	74 452	126 717	82 007





www.enzymatica.com